![Author's Photo](https://d1b6lhn2ymmy1x.cloudfront.net/journalist-headshots/biopharma/fidler-ben-square-600x600.jpg)
Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
658 articles by Ben Fidler
-
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
July 25, 2024 -
Merck claims late-stage study success for RSV antibody
July 23, 2024 -
Artiva prices $167M IPO, riding optimism for autoimmune cell therapy
July 18, 2024 -
Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex
July 16, 2024 -
Lexeo gene therapy shows signs of heart benefit in small study
July 15, 2024 -
Pfizer research chief Dolsten to step down, with company at a crossroads
July 9, 2024 -
Cartesian data add to progress, questions for CAR-T in autoimmune disease
July 2, 2024 -
With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease
July 1, 2024 -
First-of-its-kind Intellia data suggest CRISPR drug could be given more than once
June 26, 2024 -
Alnylam says heart drug succeeds in closely watched study
June 24, 2024 -
Duchenne approval exposes FDA rift over Sarepta gene therapy
June 21, 2024 -
Sarepta Duchenne gene therapy wins broader use from FDA
June 20, 2024 -
New data showcase promise, growing pains of CAR-T in autoimmune disease
June 17, 2024 -
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
June 13, 2024 -
Pfizer gene therapy for Duchenne fails to meet goals of key trial
June 12, 2024 -
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
June 10, 2024 -
With new Enhertu data, an ADC could overtake chemo in breast cancer
June 2, 2024 -
J&J gains another bispecific antibody with $1.25B skin drug buy
May 28, 2024 -
With Duchenne decision ahead, FDA’s Marks pushes for speedy gene therapy approvals
May 24, 2024 -
European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug
May 20, 2024 -
Sands Capital raises $555M fund amid upturn in biotech ‘crossover’ investing
May 14, 2024 -
NewVale, an unorthodox investment firm, sets out to support biotech’s ‘infrastructure’
May 13, 2024 -
Maze lands new partner for Pompe drug, after Sanofi pact came apart
May 10, 2024 -
Patient dies in Pfizer study of Duchenne gene therapy
May 7, 2024 -
Zenas, with new funding, aims dual-targeting antibody at lupus and MS
May 7, 2024